What the science actually says about Mochi Health (and the GLP-1 programs competing for your money)

By Bithi A· Last reviewed June 2025 · 9 min read

I’ve lost 38 pounds over six months on compounded semaglutide. I’m not a doctor. I did not get here through Mochi, Noom, or any of the other platforms that have been flooding your Instagram feed since Ozempic became a household word. But I’ve read the same trials these companies cite in their marketing, and I think most people signing up for these programs don’t know what the studies actually show, or how selectively some of that evidence gets used.

Let me walk through the real numbers.

Does semaglutide actually produce the weight loss these programs advertise?

Yes, and the effect size is real. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults with a BMI of 30 or above and randomized them to 2.4mg semaglutide weekly or placebo for 68 weeks. The semaglutide group lost 14.9% of body weight on average. Placebo lost 2.4%. That’s a 12.5 percentage-point gap, which is not a rounding error.

The mechanism isn’t mysterious. Semaglutide is a GLP-1 receptor agonist. It slows gastric emptying, reduces appetite signaling in the hypothalamus, and increases satiety. Most people on it eat less because they’re genuinely less hungry, not because they’re white-knuckling a diet.

What the marketing doesn’t always say: those results are for 2.4mg weekly, the full approved dose. Most programs start you at 0.25mg and titrate slowly. You won’t see 14.9% in month one. You won’t see it in month three.

What is Mochi Health, and what does it actually offer?

Mochi Health is a telehealth platform that prescribes GLP-1 medications, primarily semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), with some add-on coaching and dietary guidance. You pay a membership fee, do an intake, get matched with a prescriber, and receive a prescription that you fill through a pharmacy.

The company markets itself as a “holistic” weight loss program, emphasizing that it pairs medication with behavioral support. That framing matters because the behavioral support is what justifies the premium price. Mochi’s membership runs around $99/month for the platform itself, separate from medication costs. If you’re getting brand Wegovy, you’re looking at $1,349.02 per month at list price before any coupons or insurance. Compounded versions vary widely by provider.

Here’s what I’d want to know before signing up: what does “behavioral support” actually mean in practice? Mochi offers access to health coaches and registered dietitians, but access and outcomes aren’t the same thing. I haven’t seen published outcomes data specific to Mochi’s patient population. Neither have you, because it doesn’t exist publicly.

How does tirzepatide compare to semaglutide in the trials?

Tirzepatide wins on raw weight loss numbers, and it’s not particularly close. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) enrolled 2,539 adults with obesity and randomized them across three tirzepatide doses (5mg, 10mg, 15mg) and placebo. At 72 weeks, the 15mg group lost 20.9% of body weight. The 10mg group lost 19.5%. Even the 5mg group hit 15.0%.

Compare that directly to STEP 1’s 14.9% at 68 weeks and you can see why tirzepatide has become the preferred option for a lot of prescribers and patients when they can get access to it.

Tirzepatide works on both GLP-1 and GIP receptors. The dual agonism seems to produce additive effects on appetite suppression and metabolic function. Whether that translates to better long-term cardiovascular outcomes than semaglutide is still being studied.

Trial Drug Duration Max dose Weight loss (active arm) Placebo loss STEP 1 (Wilding, NEJM 2021) Semaglutide 68 weeks 2.4mg/wk 14.9% 2.4% SURMOUNT-1 (Jastreboff, NEJM 2022) Tirzepatide 72 weeks 15mg/wk 20.9% 3.1% STEP 4 (Rubino, NEJM 2021) Semaglutide 68 weeks 2.4mg/wk 17.4% (continued) vs regain Regain of 6.9%

STEP 4 is worth knowing about because it answers the question everyone asks eventually: what happens when you stop? Rubino et al. (NEJM, 2021) showed that patients who discontinued semaglutide after 20 weeks regained most of the weight within another 48 weeks. This is a chronic medication for a chronic condition. Any program that doesn’t make this explicit upfront is not being straight with you.

What about Noom? Is there evidence the coaching model works?

Noom’s model is different from Mochi’s. Noom started as a psychology-based weight loss app, built around cognitive behavioral principles and color-coded food categorization, before pivoting hard into GLP-1 prescribing after 2022. The coaching is more central to the original product.

The published evidence for Noom’s app-based behavioral approach is thin and not particularly independent. A 2016 study (Lim et al., Scientific Reports, 2016) analyzed data from 35,921 Noom users and found meaningful weight loss in engaged users, but it was conducted by Noom employees, had no randomization, and relied on self-reported outcomes. That’s not a clinical trial. That’s a company looking at its own data.

For the GLP-1 prescription side of Noom Med, the underlying medication efficacy comes from the same STEP and SURMOUNT trials that apply to everyone prescribing these drugs. Noom isn’t doing proprietary drug trials. Their differentiator is supposed to be the behavioral layer on top, and the evidence for that layer is not strong by any rigorous standard.

What is Orderly Meds, and how does it fit into this market?

Orderly Meds is a newer entry in the compounded GLP-1 space. Like several competitors, it operates as a telehealth platform connecting patients with prescribers who can write for compounded semaglutide or tirzepatide. The basic model is the same across most of these services: online intake, prescriber review, prescription to a compounding pharmacy, monthly delivery.

The meaningful differences between these platforms usually come down to four things: which pharmacy they use (503A vs. 503B), what the total monthly cost is including medication, how responsive the prescriber relationship actually is, and how they handle dose adjustments.

503B outsourced compounding facilities are FDA-registered and held to current Good Manufacturing Practice standards. 503A pharmacies compound on a per-prescription basis with less federal oversight. That’s a real quality distinction worth asking about before you hand over a credit card.

Is compounded semaglutide legitimate, and should you trust it?

The FDA’s position has shifted over the past two years, and it’s worth tracking precisely. During the Wegovy shortage, the FDA’s drug shortage list included semaglutide, which permitted 503A and 503B pharmacies to legally compound it under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. In early 2025, the FDA declared the shortage resolved and began enforcement actions against compounders continuing to produce semaglutide without meeting the conditions for exemption.

What this means practically: the legal landscape for compounded semaglutide is tighter than it was in 2023. Some platforms have pivoted to tirzepatide compounding, which remains on the shortage list as of mid-2025. You should verify the current legal status of any platform you’re considering, and confirm they’re sourcing from an FDA-registered 503B facility.

The active ingredient in compounded semaglutide is the same molecule. What varies is purity verification, excipient quality, and manufacturing consistency. A legitimate 503B facility will have a certificate of analysis for every batch. If a provider can’t tell you which pharmacy they use or won’t share batch testing documentation, that’s a red flag.

I went through a compounded GLP-1 provider after my primary care physician declined to prescribe because I didn’t have a diabetes diagnosis. The cost difference was substantial: I was quoted $1,349 per month for brand Wegovy versus roughly $299 for compounded semaglutide through FormBlends. Same active ingredient, dramatically different price.

How do you actually compare these platforms before choosing?

Price is the obvious variable, but it’s not the only one. Here’s what I’d actually look at:

Pharmacy source. Ask specifically: 503A or 503B? Can they provide the pharmacy name and a sample COA? A platform that can’t answer this is either using a 503A facility or doesn’t know what they’re doing.

Prescriber relationship. Some platforms give you an async chat with a prescriber you’ll never speak to. Others include synchronous video appointments. If you have a complicated history (thyroid nodules, pancreatitis, family history of MEN2), you want a real conversation.

Titration support. The first month on semaglutide is rough for a lot of people. I had three weeks of nausea that had me reconsidering the whole thing. A good program slows your titration down, doesn’t push you to 1mg before you’re ready. Ask how they handle nausea and GI side effects.

Total monthly cost. Get the number inclusive of the platform fee, medication, and any required add-ons. Some programs look cheap until you add the mandatory coaching subscription.

After researching several options, I ended up with compounded GLP-1 through FormBlends. The intake process was straightforward, the prescriber reviewed my labs, and I could message with questions. That’s not a guarantee your experience will be identical, but it’s what I looked for.

Frequently asked questions

Does Mochi Health use FDA-approved medications?

Mochi can prescribe both FDA-approved brand medications (Wegovy, Ozempic, Zepbound, Mounjaro) and compounded versions depending on your situation and insurance. If they’re prescribing compounded semaglutide, ask which pharmacy it comes from and whether it’s a 503B facility. The answer matters for quality assurance.

Is the weight loss on GLP-1s permanent?

The STEP 4 trial (Rubino et al., NEJM, 2021) showed that patients who stopped semaglutide regained an average of 6.9% body weight within 48 weeks, nearly reversing the loss. Most clinical guidance treats GLP-1 therapy as long-term or indefinite for patients with obesity, similar to how you’d treat hypertension medication.

What’s the difference between Noom and Mochi?

Noom started as a behavioral coaching app and added GLP-1 prescribing. Mochi started as a GLP-1 prescribing platform and added coaching. Both now offer medication plus behavioral support, but the emphasis and product architecture differ. Neither has published independent randomized controlled trial data on their specific programs.

Can I trust compounded semaglutide from an online provider?

Quality varies by pharmacy. The key question is whether your provider sources from an FDA-registered 503B outsourcing facility, which is held to current GMP standards. A reputable compounded GLP-1 provider should be able to tell you the pharmacy name and provide batch testing documentation on request.

How fast does semaglutide actually work?

Most people see noticeable appetite suppression within the first two to four weeks at even low doses (0.25mg to 0.5mg). Meaningful scale movement typically shows up by week eight to twelve. The trial results (14.9% in STEP 1, 20.9% in SURMOUNT-1) are at 68 and 72 weeks respectively. Front-loading your expectations will set you up for disappointment.

What are the real side effects I should know about?

Nausea, vomiting, constipation, and diarrhea are the most common, particularly during titration. In the STEP 1 trial, 44% of the semaglutide group reported nausea versus 16% on placebo. Most GI side effects peak in the first four to eight weeks and decrease as the body adjusts. Slower titration reduces severity significantly.

Is Orderly Meds a legitimate option?

Orderly Meds operates in the same telehealth-plus-compounding space as several competitors. The same due diligence applies: pharmacy source, prescriber access, total cost, and titration support. I haven’t used them personally and haven’t seen independent outcome data specific to their patient population. Do the same homework you’d do with any provider.

Sources

1. Wilding, J.P.H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Jastreboff, A.M., et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
3. Rubino, D., et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.” New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2106364
4. Lim, S., et al. “Longitudinal Study to Evaluate the Weight Loss Effectiveness of a Smartphone App-Based Mobile Weight Management Program.” Scientific Reports, 2016. https://www.nature.com/articles/srep34941
5. U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
6. U.S. Food and Drug Administration. “FDA Updates on Compounded Semaglutide and Tirzepatide.” FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/updates-semaglutide-compounding